SCHEMBL798484

SCHEMBL798484

O=C(O)c1csc(Nc2ccccc2F)n1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
KDM1A O60341 1/20 0.55
L3MBTL1 Q9Y468 2/20 0.50
MEN1 O00255 1/20 0.50
CDK5 Q00535 1/20 0.50
KMT2A Q03164 1/20 0.50
CDK5R1 Q15078 1/20 0.50
ACHE P22303 1/20 0.50
POLB P06746 1/20 0.50
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
ALOX15 P16050 1/20 0.48
SMN1; SMN2 Q16637 1/20 0.48
HSD17B10 Q99714 1/20 0.48
GAA P10253 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 1/20 0.47
ATM Q13315 1/20 0.47
ROCK1 Q13464 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4927035 0.84 CCR4 (0.57) NPC1RAB9AKDM1AL3MBTL1MEN1
SCHEMBL798528 0.84 NPC1 (0.77) NPC1RAB9AKDM1AL3MBTL1MEN1
SCHEMBL790034 0.82 SMN1; SMN2 (0.60) NPC1RAB9AKDM1AL3MBTL1MEN1
SCHEMBL2285389 0.81 AMY1A (0.60) NPC1RAB9AKDM1AL3MBTL1MEN1
SCHEMBL23742669 0.80 NPC1 (0.53) NPC1RAB9AMEN1KMT2ASMN1; SMN2
SCHEMBL23742673 0.80 CSNK2A1 (0.67) NPC1RAB9AMEN1KMT2AALDH1A1
SCHEMBL14422240 0.80 NPC1 (0.52) NPC1RAB9AKDM1AL3MBTL1MEN1
SCHEMBL3604259 0.78 RAB9A (0.70) NPC1RAB9AL3MBTL1MEN1KMT2A
SCHEMBL23722675 0.78 CSNK2A1 (0.60) NPC1RAB9AMEN1KMT2APOLB
SCHEMBL14422243 0.77 RAB9A (0.51) NPC1RAB9AKDM1AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3645531-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS Bayer Aktiengesellschaft (DE) 2020-05-06 EP disclosed
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2020-04-23 US disclosed
WO-2019002074-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS BAYER AKTIENGESELLSCHAFT (DE) 2019-01-03 WO disclosed
WO-2012037351-A1 COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed
WO-2012037349-A2 COMPOUNDS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200123147-A1 THIAZOLE COMPOUNDS USEFUL AS PRMT5 INHIBITORS PRMT5, PRMT1, PRMT6 NPC1 2953/4885RAB9A 2145/4885KDM1A 162/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.